Preoperative plasma miR-144-3p to predict persistent type 2 diabetes after gastric bypass – a pilot proof-of-concept study
Authors' conclusion
Overall, these findings identify preoperative miR-144-3p as a candidate biomarker for predicting persistent T2DM after RYGB.
Study context
- Population
- Women with obesity and T2D undergoing RYGB, assessed preoperatively and at 3, 12 and 60 months
- Participants
- 28 women
- Exposure
- Non-responders vs responders
- Rn = 18reference
- Non-responders (NR)n = 10
- Outcome
- Prediction of persistent T2D after RYGB by preoperative circulating microRNAs (miRNAs)
Methodological detailspilot proof-of-concept
- Pilot proof-of-concept
Main finding
As reported in the abstract
Preoperative miR-144-3p predicting persistent T2D (RT-qPCR validation, full cohort)
AUC of elevated preoperative miR-144-3p, p = 0.023
0.771
Specificity
100 %
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| miR-144-3p at 3 months in R patients who relapsed at 5 years vs those maintaining remissionHigher in relapsed · post hoc exploratory analysis | P < 0.0001 |
- Preoperative miR-144-3p expression, screening phase (TaqMan Low Density Array, n = 17) — miR-144-3p correlated inversely with plasma insulin · higher in NR
- P = 0.018 · P = 0.033
Original publication
Preoperative plasma miR-144-3p to predict persistent type 2 diabetes after gastric bypass – a pilot proof-of-concept study. Diabetes Res Clin Pract. Published 10 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →